Karol Watson, MD, PhD
Professor of Medicine/Cardiology at the David Geffen School of Medicine at UCLA
Director of the UCLA Women’s Cardiovascular Health Center
Director, UCLA-Barbra Streisand Women’s Heart Health Program
Co-Director, UCLA Program in Preventive Cardiology
Director, UCLA Fellowship Program in Cardiovascular Diseases
Dr. Watson is a principal investigator for several large National Institutes of Health research studies including the Diabetes Prevention Program Outcomes Study and the Multi-ethnic Study of Atherosclerosis. She is a Fellow of the American College of Cardiology and a member of the American Heart Association. She is also a Board member of the American Heart Association, Western States Affiliate, and Chairperson of the Scientific Advisory Board for Womenheart, the largest national organization for women survivors of heart disease.
Live Webcast: Video Link | Meeting ID: 746-346-8349
INTENDED LEARNERS
This activity is designed for cardiologists and cardiology-related healthcare professionals including residents, fellows, nurse practitioners, physician assistants, pharmacists, nurses and other healthcare professionals involved in the care of patients with hypercholesterolemia.
LEARNING OBJECTIVES
After completing this activity, participants should be able to:
- Review the latest clinical trial evidence supporting the use of PCSK9 inhibitor therapies within the secondary prevention of cardiovascular events
- Examine updates to guideline recommendations and expert consensus statements regarding the role of non- statin therapies for the treatment of hypercholesterolemia and management of established CVD
- Identify specific patient populations that would benefit from LDL-C lowering utilizing PCSK9 inhibitor therapies
- Develop strategies to overcome barriers that preclude access to PCSK9 inhibitors despite FDA-approved indications, including prior authorizations, Insurance denials, and inconsistencies in the interpretation of prescription language
- Translate the latest evidence, updated guidelines, and potential resolutions to access-related barriers to the individualized and targeted treatment of hypercholesterolemia and management of established CVD
ACCREDITATION
In support of improving patient care, North American Center for Continuing Medical Education (NACCME)is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME),the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
CME
NACCME designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE
This continuing nursing education activity awards 1.0 contact hour.
Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.0 contact hour.
CPE
This activity is approved for 1.0 contact hour (0.1 CEU) of continuing pharmacy education (UAN JA0006201-0000- 18-076-L01-P).
This educational activity is a knowledge-based activity.
This activity is supported by educational funding provided by Amgen and Sanofi US and Regeneron Pharmaceuticals.
Activity provided by North American Center for Continuing Medical Education, LLC, an HMP Company
